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Background: Proton-pump inhibitor (PPI) medications are prescribed on the initiation of thienopyridines. It is unknown whether concomitant use 
of a PPI attenuates the pharmacodynamic effect or clinical efficacy of clopidogrel or ticropidine. We assessed the association between the use of a 
PPI, measurements of platelet function, and clinical outcomes for patients treated with clopidogrel or ticlopidine. 
Methods: The study population consisted of 424 patients with stable angina who had undergone successful drug-eluting stent implantation. We 
measured whole-blood platelet aggregation at stenting, using the screen filtration pressure method with adenosine diphosphate as an agonist. 
The concentration of adenosine diphosphate required to induce 50% of the maximum pressure rate was calculated and taken as the platelet 
aggregatory threshold index (PATI) (μM/L). All patients received 75mg of clopidogrel (n=121) or 200mg of ticlopidine (n=303) and 100mg of aspirin 
daily for a minimum of 1 week before stenting. The primary endpoint was the composite of cardiovascular death, myocardial infarction or target-
vessel revascularization at 12-month follow-up. The type of thienopyridines or PPI used was at the physician’s discretion. 
Results: Mean PATI level was significantly lower for patients (n=49) on a PPI than for those (n=72) not on a PPI in the clopidogrel group ( 6.7±4.7 
vs 9.7±5.7, p=0.003), whereas no significant difference was seen with (n=71) or without (n=232) a PPI in the ticlopidine group ( 8.5±5.4 vs 
9.6±5.3, p=0.135). There was no association between PPI use and risk of the primary endpoint for patients treated with clopidogrel (odds ratio [OR] 
1.30, 95% CI 0.41-4.12) or ticlopidine (OR 1.22, 95%CI 0.62-2.40). 
Conclusion: This study shows that PPI use may attenuate the pharmacodynamic effect of clopidogrel without affecting clinical efficacy.
